In a head-to-head trial, 70% improved on copper peptides versus 40% on retinoids and 50% on vitamin C
Once in the bloodstream, cibinetide binds this receptor on immune cells (especially myeloid cells like macrophages and microglia), endothelial cells, and other stressed tissues, triggering intracellular signaling (e.g., JAK/STAT, PI3K/Akt, and inhibition of NF-B p65) that dampens innate immune overactivation, suppresses production and systemic release of pro-inflammatory cytokines (TNF-, IL-1, IL-6, IL-12/IL-23), reduces chemokine-driven cell infiltration, lowers oxidative stress and nitric oxide overproduction, and promotes anti-inflammatory shifts and cell survival
Some patients report initial improvements in symptoms within 1-2 weeks, while more significant healing typically develops over 4-8 weeks
MOTs-C works by regulating mitochondrial energy
Another BBB-crossing molecule with HGF-like activity, BB3, was employed in pre-clinical models of stroke, showing good functional improvements (Chaparro et al., 2015)
Yes each COA carries the issuing laboratory name and report ID
.png)
